Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06311916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06311916 · ClinicalTrials.gov record · last posted 2024-03-15

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

Name: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. — clinical trial record (NCT06311916)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorChen Xiaoping

Started2024-05-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). The intermediate stage (BCLC-B) HCC is highly heterogeneous, and there is no consensus on the treatment of this stage of the tumor in Western and Eastern countries. New tools are urgently needed to guide the choice of treatment options for patients with this stage of the tumor in order to reduce the risk of postoperative recurrence and the overall survival rate.

Trial Details

NCT Number	NCT06311916
Lead Sponsor	Chen Xiaoping
Conditions	HCC
Enrollment	312 participants
Start Date	2024-05-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-03-15